Overview of CRISPR-Cas Mediated Genome Engineering
T. G. Bhuvana *
Department of Biotechnology, Ramaiah Institute of Technology, MSR Nagar-Bangalore, Karnataka, India.
N. Ranjitha
Department of Biotechnology, Ramaiah Institute of Technology, MSR Nagar-Bangalore, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Genetic diseases are prevailing in 3-5% of new-born worldwide and estimated to cause around 50% of child deaths. The development of efficient and regulated system for customizing genome modifications to treat such disorders has been the zone of interest. Over time, different editing techniques have emerged based on programmable nucleases such as ZFN or TALENS but among all, CRISPR-Cas has significantly progressed as alteration tool from bench to clinical practices. CRISPR-Cas is an immune system discovered in prokaryotes that enables organism to recognize and destroy any invading genetic elements. This functional property of CRISPR has opened up plethora of applications across different disciplines such as diagnostics, agriculture and therapeutics. So here, the review attempt to discuss origin, mechanisms pertinent to CRISPR and applications along with challenges concerning them.
Keywords: Genome editing, CRISPR-Cas, genetic disorder, disease model, agriculture, bioenergy, therapeutics
How to Cite
Downloads
References
Hille F, Charpentier E. CRISPR-cas: Biology, mechanisms and relevance. Philosophical Transactions of the Royal Society B: Biological Sciences; 2016.
Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, et al. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life Sci. Elsevier Inc.; 2019.
Mei Y, Wang Y, Chen H, Sun ZS, Ju X Da. Recent Progress in CRISPR/Cas9 Technology. Journal of Genetics and Genomics. Elsevier. 2016;63–75.
Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: Biology, mechanisms and applications. Biochimie. Elsevier. 2015;117:119–28.
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
Moon S Bin, Kim DY, Ko JH, Kim YS. Recent advances in the CRISPR genome editing tool set. Exp Mol Med. Springer Nature. 2019;51.
Gaj T, Sirk SJ, Shui SL, Liu J. Genome-Editing technologies: Principles and applications. Cold Spring Harb Perspect Biol. Cold Spring Harbor Laboratory Press. 2016;8.
Mengstie MA, Wondimu BZ. Mechanism and applications of CRISPR/ Cas-9-Mediated Genome Editing; 2021.
Kozovska Z, Rajcaniova S, Munteanu P, Dzacovska S, Demkova L. CRISPR: History and perspectives to the future. Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l. 2021;141.
Han W, She Q. CRISPR history: Discovery, characterization, and prosperity. Prog Mol Biol Transl Sci. Academic Press. 2017;152:1–21.
Makarova KS, Haft DH, Barrangou R, J Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR–Cas systems; 2011.
Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. Elsevier Current Trends. 2017; 37:67–78.
Makarova KS, Wolf YI, Koonin EV. Classification and nomenclature of CRISPR-Cas systems: Where from here? CRISPR J. Mary Ann Liebert Inc. 2018;1: 325–36.
Horvath P, Barrangou R. CRISPR/Cas, the immune system of Bacteria and Archaea. Science (1979). American Association for the Advancement of Science. 2010;327: 167–70.
Nussenzweig PM, Marraffini LA. Molecular mechanisms of CRISPR-Cas immunity in bacteria. Annu Rev Genet. Annual Reviews Inc. 2020;54:93–120.
Yang H, Ren S, Yu S, Pan H, Li T, Ge S, et al. Methods favoring homology-directed repair choice in response to CRISPR/Cas9 induced-double strand breaks. Int J Mol Sci. Int J Mol Sci. 2020; 21:1–20.
Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR–Cas systems; 2015.
Mohr SE, Hu Y, Ewen-Campen B, Housden BE, Viswanatha R, Perrimon N. CRISPR guide RNA design for research applications. FEBS Journal. Blackwell Publishing Ltd. 2016;3232–8.
Anton T, Karg E, Bultmann S. Applications of the CRISPR/Cas system beyond gene editing. Biol Methods Protoc [Internet]. Oxford University Press. 2018 [cited 2022 Oct 6];3.
Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994046/
Liu Z, Dong H, Cui Y, Cong L, Zhang D. Application of different types of CRISPR/Cas-based systems in bacteria. Microbial Cell Factories 2020 19:1. BioMed Central. 2020;19:1–14.
Antoniou P, Miccio A, Brusson M. Base and prime editing technologies for blood disorders. Front Genome Ed. Frontiers. 2021;0:1.
Cohen J. New ‘prime’ genome editor could surpass CRISPR. Science (1979). American Association for the Advancement of Science (AAAS); 2019.
Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149.
Yang G, Huang X. Methods and applications of CRISPR/Cas system for genome editing in stem cells. Cell Regeneration. KeAi Communications Co. 2019;33–41.
Waddington SN, Privolizzi R, Karda R, O’Neill HC. A broad overview and review of CRISPR-Cas technology and stem cells. Curr Stem Cell Rep. 2016;9–20.
Lin H, McBride KL, Garg V, Zhao MT. Decoding genetics of congenital heart disease using patient-derived induced Pluripotent Stem Cells (iPSCs). Front Cell Dev Biol. Frontiers Media S.A. 2021;9.
Bai X. Stem Cell-Based Disease Modeling and Cell Therapy. Cells. 2020 Sep 29;9(10):2193.
Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduction and Targeted Therapy. 2020;5, Article number: 1.
Ebrahimi S, Khanbabaei H, Abbasi S, Fani M, Soltani S, Zandi M, et al. CRISPR-Cas system: A promising diagnostic tool for Covid-19. Avicenna J Med Biotechnol. 2022;14:3–9.
Berber B, Aydin C, Kocabas F, Guney-Esken G, Yilancioglu K, Karadag-Alpaslan M, et al. Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics. Gene Therapy 2020 28:6. Nature Publishing Group. 2020;28:290–305.
Javed MR, Noman M, Shahid M, Ahmed T, Khurshid M, Rashid MH, et al. Current situation of biofuel production and its enhancement by CRISPR/Cas9-mediated genome engineering of microbial cells. Microbiol Res. Microbiol Res. 2019;219:1–11.
Umar Ibrahim A. Application of Crispr technology for the generation of biofuels: A review. Journal of Fundamentals of Renewable Energy and Applications Article in Journal of Fundamentals of Renewable Energy and Applications. [Internet]; 2019. [Cited 2022 Oct 8].
Estrela R, Cate JHD. Energy biotechnology in the CRISPR-Cas9 era. Curr Opin Biotechnol. Elsevier Ltd. 2016;79–84.
Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. NIH Public Access. 2014;157:1262.
Zhu H, Li C, Gao C. Applications of CRISPR–Cas in agriculture and plant biotechnology. Nat Rev Mol Cell Biol. Nature Research. 2020;661–77.
Zaidi SS e. A, Mahas A, Vanderschuren H, Mahfouz MM. Engineering crops of the future: CRISPR approaches to develop climate-resilient and disease-resistant plants. Genome Biology. BioMed Central. 2020;21:1–19.
Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A. Optical control of CRISPR/Cas9 gene editing. J Am Chem Soc. American Chemical Society. 2015; 137:5642–5.
Hoffmann MD, Mathony J, Upmeier Zu Belzen J, Harteveld Z, Aschenbrenner S, Stengl C, et al. Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein. Nucleic Acids Res. Oxford University Press. 2021; 49:1–11.
Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol. Nature Publishing Group. 2015;33:755–60.
Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nat Chem Biol. Nature Publishing Group. 2015;11: 198–200.
Tavakoli K, Pour-Aboughadareh A, Kianersi F, Poczai P, Etminan A, Shooshtari L. Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences. BioTech. Multidisciplinary Digital Publishing Institute. 2021;10:14.
Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF. CRISPR/Cas9 for sickle cell disease: Applications, future possibilities, and challenges. Adv Exp Med Biol. Springer New York LLC. 2019; 37–52.
Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-Thalassemia. New England Journal of Medicine. 2021;384:252–60.
Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging therapeutic approaches for cystic fibrosis. From Gene Editing to Personalized Medicine. Front Pharmacol. Frontiers Media SA. 2019;10.
Bergeron C, Cantin AM. New therapies to correct the cystic fibrosis basic defect. Int J Mol Sci. 2021;22.
Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. Nature Publishing Group. 2015;15:387–95.
Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. Semin Cancer Biol. 2019;55:106–19.
Yin H, Xue W, Anderson DG. CRISPR–Cas: A tool for cancer research and therapeutics. Nat Rev Clin Oncol. Nature Publishing Group. 2019;281–95.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (1979). American Association for the Advancement of Science. 2020;367.
Anliker B, Childs L, Rau J, Renner M, Schüle S, Schuessler-Lenz M, et al. Regulatory considerations for clinical trial applications with CRISPR-Based medicinal products. NY 10801 USA. 2022;5:364–76.
Strich JR, Chertow DS. CRISPR-Cas biology and its application to infectious diseases. J Clin Microbiol. 2019;57.